hTH-GFP Rat (Autosomal Insertion)

hTH-GFP (Autosomal Insertion) Rat Model

NTac:SD Background

  • Model #
  • Genotype
  • Nomenclature
  • 12108-F
    tg/wt
    NTac:SD-Tg(TH-EGFP)7Xen
  • 12108-M
    tg/wt
    NTac:SD-Tg(TH-EGFP)7Xen
  • Carries an EGFP transgene driven by the human Tyrosine Hydroxylase (hTH) promoter.
  • The hTH-GFP transgene is NOT located on the X chromosome. This is a key difference from model 12141 (X-linked transgene). Additionally, model 12108 exhibits ectopic GFP expression in olfactory bulb whereas the GFP expression in model 12141 (the X-linked version) has more specificity for TH neurons.
  • High level EGFP expression observed in dopaminergic neurons in brain structures such as, substantia nigra, ventral tegmental area, striatum, olfactory bulb, and hypothalamus, with minimal ectopic expression elsewhere in the brain.
  • Dopamine neurons are susceptible to damage/loss in Parkinson's disease and therefore this rat can be used as a tool to study damage/loss of dopamine neurons, e.g., after MPTP or 6-OHDA treatment.
  • Useful for in vivo anatomical visualization and micro-dissection of rat midbrain structures and axonal projections. High EGFP expression permits fluorescence imaging of brain slices.
  • Useful for FACS purification and in vitro culture of dopamine neurons for studies of disease pathogenesis in culture. Since EGFP is more easily detected than TH immunostaining at early developmental stages, this rat may be particularly useful for early embryonic studies of the development of dopamine neurons.
  • Since EGFP is more easily detected than TH immunostaining at early developmental stages, this rat may be particularly useful for early embryonic studies of the development of dopamine neurons.

Origin:

The hTH-GFP rat was developed in collaboration between The Michael J Fox Foundation, Thomas Jefferson University, and Taconic. DNA fragments including 10.794 kb of the distal hTH promoter and 1.168 kb of proximal hTH promoter were ligated and placed upstream of the GFP reporter gene to create the hTH-GFP construct. This model was created through pronuclear injection of the hTH-GFP construct into NTac:SD zygotes. hTH-GFP founder line 7 (model 12108) was bred to NTac:SD for initial characterization. The colony is maintained by mating a NTac:SD female with a hemizygous male to produce hemizygous pups.


Source:

Model Sponsor: The Michael J. Fox Foundation

Availability:

Available off-the shelf. Limited breeding pairs available.

Color:

Albino

Species:

Rat

Initial Publication:

Iacovitti L, Wei X, Cai J, Kostuk EW, Lin R, et al. (2014) The hTH-GFP Reporter Rat Model for the Study of Parkinson’s Disease. PLoS ONE 9(12): e113151. doi:10.1371/journal.pone.011315




The hTH-GFP Rat Model may be purchased by nonprofit users under the following label license (no signatures required). For-profit users must first be confirmed to have a valid license from GE Healthcare UK Ltd prior to purchase of the hTH-GFP Rat Model under the following label license (no signatures required).

LABEL LICENSE AGREEMENT FOR hTH-GFP RAT

The hTH-GFP Rat Model (“Model”) is produced and distributed under rights to patents and/or intellectual property owned by or licensed to the Michael J. Fox Foundation (“MJFF”) and Taconic. Taconic has rights to distribute the Model on behalf of MJFF. MJFF maintains ownership of the Model and permits the sale of such model to each purchaser that is (i) a nonprofit institution or (ii) a for-profit institution having a license from GE Healthcare UK Ltd, and that agrees to the Terms and Conditions of the Sale and following terms of use:

  • Title to the Model, any progeny, and biological materials derived from the foregoing remains with MJFF.
  • The Model may be bred or crossbred by purchaser
  • Purchaser shall inform MJFF of any crossbred animal generated (“Modified Progeny”), shall at MJFF's election deposit breeding pairs of each Modified Progeny with Taconic or another designee of MJFF and shall permit Taconic or another designee of MJFF to distribute the Modified Progeny on behalf of MJFF to nonprofit institutions or for-profit institutions without any compensation to purchaser on terms similar to the terms and conditions by which purchaser received the Model. Purchaser assumes all liability for any claim or demand that Modified Progeny created by purchaser infringes on the intellectual property rights of any third party.
  • The Model, progeny, or Modified Progeny may be used for research purposes only.
  • The Model, any progeny, Modified Progeny, or biological materials will not be used for commercial purposes.
  • The Model, any progeny, Modified Progeny, and biological materials derived from them will not be distributed to any third party.
  • Purchaser assumes all risk from using the Model, any progeny, Modified Progeny, and biological materials.
  • To the extent permissible by law, purchaser indemnifies, defends, and holds harmless MJFF from any claim or demand that purchaser's use or transfer of the Model, any progeny, Modified Progeny, or biological materials has caused harm, damage, or liability.
  • Each purchaser agrees to comply with the “Label License Agreement for End Users” required by GE Healthcare UK Ltd a copy of which is attached hereto.
LABEL LICENSE AGREEMENT FOR END USERS
BY OPENING THE PACKAGING ENCLOSING THE TRANSGENIC ANIMAL(S), YOU ACCEPT THE TERMS AND CONDITIONS BELOW.
LICENSE TO USE THE TRANSGENIC ANIMAL(S). IMPORTANT INSTRUCTIONS — READ CAREFULLY: This Label License Agreement (the “Label License Agreement”) is a legal agreement between you (“End User”) and GE Healthcare UK Ltd (“GEHC”) to use Transgenic Animals containing materials containing fluorescent proteins and/or genes covered by patents owned or controlled by GEHC which are provided to you by GEHC’s sub-licensee, TaconicArtemis (“Sub-Licensee”), which Transgenic Animals shall be referred to herein as “Transgenic Animals”.
AS A CONDITION OF THE TRANSFER AND USE OF THE TRANSGENIC ANIMALS AND PRIOR TO THE OPENING OF PACKAGING ENCLOSING THE TRANSGENIC ANIMALS, GEHC AND END USER AGREE TO THE FOLLOWING TERMS AND CONDITIONS AS SET FORTH HEREIN. END USER ACKNOWLEDGES THAT IT WAS NOTIFIED PRIOR TO RECEIVING THE TRANSGENIC ANIMALS THAT THE TRANSFER AND USE OF THE TRANSGENIC ANIMALS ARE SUBJECT TO THESE TERMS AND CONDITIONS AND WAS PROVIDED A COPY OF THESE TERMS AND CONDITIONS IN SUBSTANTIALLY THE SAME FORM AS HEREIN. IF END USER DOES NOT AGREE TO ALL OF THE TERMS AND CONDITIONS HEREIN, END USER SHALL IMMEDIATELY RETURN ALL TRANSGENIC ANIMALS TO SUB-LICENSEE.
  1. Controlling Terms. Any terms or conditions set forth by Sub-Licensee in any writing or otherwise, including any purchase order, acknowledgment, or confirmation, which are different from or in addition to those contained herein shall (as between End User and GEHC) be null and void and shall have no binding effect whatsoever, unless agreed to in writing by GEHC. Absent such separate written agreement, such different, or additional terms are hereby rejected by GEHC.
  2. Warranties. The End User hereby irrevocably represents, warrants and undertakes to GEHC as follows:-
    • 2.1 unless it is a university, government agency, or other similar nonprofit organisation, the End User has a valid and subsisting in-license under which it is entitled to receive and use the Transgenic Animals for the purposes specified in this Label License Agreement and that it will maintain such license in accordance with its terms during all times when it has possession, control, or use of the Transgenic Animals;
    • 2.2 the End User will not transfer any Transgenic Animal to any third party save as may be expressly authorized in a separate written agreement with GEHC;
    • 2.3 the End User will keep and use the Transgenic Animals in accordance with the restrictions and limitations contained in this Label License Agreement and, if appropriate, in accordance with its aforesaid in-license.
  3. Proprietary Rights. The Transgenic Animals may be covered by one or more of the following patents: (1) US 6 172 188, EP 851874, US 5 958 713 and EP 0815257, and under international patent application PCT/EP01/06848 and other pending and foreign patent applications; and (2) US 5 625 048, US 5 777 079, US 5 804 387, US 5 968 738, US 5 994 077, US 6 054 321, US 6 066 476, US 6 077 707, US 6 090 919, US 6 124 128, US 6 319 669, US 6,403,374, EP 0804457, EP 1104769, JP 3283523 and other pending and foreign patent applications. By entering into this Label License Agreement, End User acknowledges that the Transgenic Animals are so covered.
  4. Excluded Fields. No permission is granted hereunder for the use of the Transgenic Animals for the provision of services to third parties, or: in agrochemistry, environmental, and veterinary applications, in diagnostics, in or with plants (including plant cells) and/or uses related to food products, flavors, fragrances and/or taste enhancers (together the “Excluded Fields”).
  5. Use by the End User. Subject to Clause 4 above End User will use the Transgenic Animals solely for research for the discovery and development of human therapeutics outside the Excluded Fields by End User and will not sell, transfer, disclose or otherwise provide access to the Transgenic Animals or any materials containing fluorescent proteins and/or genes covered by patents owned or controlled by GEHC to any third party or entity. Unless expressly licensed in a separate written agreement with GEHC, End User shall not have the right to authorize any third party to make, use or sell any materials or any analogs or derivatives thereof containing fluorescent proteins and/or genes covered by patents owned or controlled by GEHC.
  6. Disclaimer of Warranties. GEHC HEREBY DISCLAIMS ALL REPRESENTATIONS, CONDITIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OR CONDITION OF NON-INFRINGEMENT, TITLE, QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.
  7. Limitation of Liability. IN NO EVENT SHALL END USER BE ENTITLED TO RECOVER FROM GEHC ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES (INCLUDING LOSS OF: PROFIT, OPPORTUNITY, BUSINESS, SAVINGS, OR REPUTATION) IN CONNECTION WITH THIS AGREEMENT OR THE LICENSE GRANTED HEREUNDER.